Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
JAMA Ophthalmol. 2024 Sep 1;142(9):827-834. doi: 10.1001/jamaophthalmol.2024.2749.
Long-term trend analyses of overall endophthalmitis rates and treatment patterns are scarce. It is also unknown if the deviation from the recommendations of the Endophthalmitis Vitrectomy Study toward decreased utilization of vitrectomy is associated with different vision outcomes.
To determine whether the rate of endophthalmitis after intraocular procedures or the primary treatment (prompt vitrectomy vs tap and inject) for endophthalmitis has changed over the past 20 years.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study examined data for cohorts created by querying for different intraocular procedures, including intravitreal injections and surgeries for cataract removal, glaucoma, retinal conditions, and corneal transplants from 2000 to 2022. The data source was a US administrative medical claims database comprising commercial and Medicare Advantage insurance plans. Any intraocular procedure with at least 6 months of data available before and 6 weeks after the procedure was eligible. Exclusion criteria consisted of any previous diagnosis of endophthalmitis or another intraocular procedure during the follow-up period.
The main outcomes were rate of postprocedure endophthalmitis and relative rate of prompt vitrectomy (vs tap and inject) as the primary method of treatment.
Among 2 124 964 patients, the mean (SD) age was 71.4 (10.2) years; 1 230 320 were female and 894 414 male. Over 22 years, 5 827 809 intraocular procedures were analyzed with 4305 cases of endophthalmitis found for an overall endophthalmitis rate of 0.07%. The yearly rate of endophthalmitis varied but generally declined from a high of 7 cases per 3502 procedures (0.20%) in 2000 to a low of 163 cases per 332 159 procedures (0.05%) in 2022. The percentage of cases treated with prompt vitrectomy also varied but generally declined over time with a high of 17 of 35 (48.6%) in 2003 and a low of 60 of 515 (11.6%) in 2021. Multivariable analysis of the endophthalmitis incidence rate ratio (IRR) showed a per-year decrease of 2.7% (IRR, 0.97; 95% CI, 0.97-0.98; P < .001) over the study period. A similar analysis also showed that the incidence rate of prompt surgical treatment decreased by 3.8% per year throughout the study period (IRR, 0.96; 95% CI, 0.95-0.97; P < .001).
This study found that the incidence of endophthalmitis following intraocular procedures appears to have decreased substantially over the past 20 years while prompt vitrectomy is being used less frequently as primary treatment than in the past.
长期的眼内炎总体发生率和治疗模式趋势分析较为缺乏。此外,对于玻璃体切除术应用减少是否与不同的视力结果相关,目前仍不清楚这一现象是否偏离了眼内炎玻璃体切除术研究的建议。
旨在确定过去 20 年来,眼内手术后眼内炎的发生率或眼内炎的主要治疗方法(及时玻璃体切除术与玻璃体切割术联合眼内注药)是否发生了变化。
设计、地点和参与者:本队列研究通过查询 2000 年至 2022 年期间不同的眼内手术(包括眼内注射和白内障、青光眼、视网膜疾病和角膜移植手术),创建了队列数据。数据来源是美国一个行政医疗索赔数据库,包括商业保险和 Medicare Advantage 保险计划。只要在手术前后 6 个月内有至少 6 周的数据,就符合纳入标准。排除标准包括在随访期间有先前的眼内炎或其他眼内手术诊断。
主要结局是术后眼内炎的发生率和及时玻璃体切除术(与玻璃体切割术联合眼内注药相比)作为主要治疗方法的相对发生率。
在 2124964 名患者中,平均(SD)年龄为 71.4(10.2)岁;1230320 名女性和 894414 名男性。在 22 年的时间里,共分析了 5827809 例眼内手术,发现 4305 例眼内炎,总体眼内炎发生率为 0.07%。眼内炎的年发生率有所波动,但总体呈下降趋势,从 2000 年的每 3502 例手术中有 7 例(0.20%)的高峰降至 2022 年的每 332159 例手术中有 163 例(0.05%)的低谷。及时玻璃体切除术治疗的比例也有所波动,但总体随时间呈下降趋势,2003 年最高,35 例中有 17 例(48.6%),2021 年最低,515 例中有 60 例(11.6%)。眼内炎发生率的多变量分析显示,研究期间每年下降 2.7%(发病率比,0.97;95%置信区间,0.97-0.98;P < 0.001)。类似的分析还表明,整个研究期间及时手术治疗的发生率每年下降 3.8%(发病率比,0.96;95%置信区间,0.95-0.97;P < 0.001)。
本研究发现,过去 20 年来,眼内手术后眼内炎的发生率似乎大幅下降,而及时玻璃体切除术作为主要治疗方法的应用频率却低于过去。